Gubra (GUBRA) Partnership summary

Opening remarks and agenda

• Announcement of a transformative partnership between AbbVie and Gubra for the GUBamy Amylin Program (GUB014295), marking AbbVie's entry into the obesity field, with participation from both companies' leadership.

• Analyst and investor presentation scheduled, hosted by Gubra's CEO, CSO, and CFO.

Objectives of the partnership

• Accelerate development and commercialization of GUBamy (GUB014295) in the obesity market by leveraging AbbVie's global infrastructure and resources.

• Address significant unmet needs in obesity care and foster long-term growth.

Partner introductions and roles

• AbbVie will take over global development and commercialization of GUBamy (GUB014295) after closing.

• Gubra specializes in preclinical research and peptide-based drug discovery, focusing on early-stage development, and retains eligibility for upfront, milestone, and royalty payments.